Other substances

P5A-3C12

A human monoclonal anti-RBD (SARS-CoV-2) antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

P5A-3C12 is a human monoclonal IgG antibody identified in COVID-19 convalescent patient serum. It binds SARS-CoV-2 RBD and neutralizes the virus in vitro (Yan et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Spike protein Cryo-EM Biophysical assay In vitro Antibody 		in vitro biophysical assay; cryo-EM; Huh7 cells; Vero E6 cells; (HIV) SARS-CoV-2 Spike pseudovirus; SARS-CoV-2 isolate Beta/Shenzhen/SZTH-003/2020 20.51

The antibody bound SARS-CoV-2 Spike protein RBD and neutralized SARS-CoV-2 live virus and Spike pseudovirus in vitro with IC50s of 1.76 nM and 0.66 nM, respectively.).

 Mar/17/2021
Export (.csv)